Erratum to: Efficacy and Safety of the PCSK9 Inhibitor Evolocumab in Patients with Mixed Hyperlipidemia.
about
Erratum to: Efficacy and Safety of the PCSK9 Inhibitor Evolocumab in Patients with Mixed Hyperlipidemia.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh
2016年學術文章
@zh-hant
name
Erratum to: Efficacy and Safet ...... nts with Mixed Hyperlipidemia.
@en
Erratum to: Efficacy and Safet ...... nts with Mixed Hyperlipidemia.
@nl
type
label
Erratum to: Efficacy and Safet ...... nts with Mixed Hyperlipidemia.
@en
Erratum to: Efficacy and Safet ...... nts with Mixed Hyperlipidemia.
@nl
prefLabel
Erratum to: Efficacy and Safet ...... nts with Mixed Hyperlipidemia.
@en
Erratum to: Efficacy and Safet ...... nts with Mixed Hyperlipidemia.
@nl
P2093
P1476
Erratum to: Efficacy and Safet ...... ents with Mixed Hyperlipidemia
@en
P2093
Ian Bridges
Michael Miller
Ricardo Dent
Robert S Rosenson
Stephen C Djedjos
P356
10.1007/S10557-016-6684-Z
P577
2016-10-01T00:00:00Z